No abstract

In a double blind randomized crossover trial lasting 6 months selegiline, a selective MAO-B inhibitor, was tested against placebo for activity on verbal memory performances in Alzheimer-type dementia (DAT). Verbal memory was assessed with the Rey-Auditory-Verbal Learning Test at the start of treatment, at the time scheduled for crossover (90 days) and at the end of the trial (180 days). The results suggest that selegiline possesses significant activity on some memory parameters, which seems to depend on an improvement both in information processing abilities and in learning strategies at the moment of acquisition.

SummaryPiroxicam-J3-cyclodextrin has been shown to give pain relief comparable to that with indomethacin and significantly greater than that with naproxen and piroxicam alone in the treatment of primary and migraine headaches. In addition, it would appear to be of use in the prophylaxis of migraine headaches, although further studies are required. The incidence of side effects with piroxicam-J3-cyclodextrin was substantially less than that with comparable drugs, particularly with regard to gastrointestinal side effects. In view of its efficacy, tolerability and apparent prophylactic properties, piroxicam-J3-cyclodextrin would appear to be a useful analgesic in the treatment of primary or migraine headaches.

No abstract